Anzeige
Mehr »
Donnerstag, 15.05.2025 - Börsentäglich über 12.000 News
Verpasst du gerade die Buffett-Aktie der neuen Generation?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A4091K | ISIN: US6294442099 | Ticker-Symbol: B1Q
Frankfurt
15.05.25 | 09:59
1,950 Euro
-7,14 % -0,150
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
NRX PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
NRX PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur NRX PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiUncovering Potential: NRX Pharmaceuticals' Earnings Preview2
DiHOPE Therapeutics and NRx Pharmaceuticals to buy Kadima Institute3
NRX PHARMACEUTICALS Aktie jetzt für 0€ handeln
DiNRX Pharmaceuticals, Inc. - 8-K, Current Report1
DiHOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute120Kadima Neuropsychiatry Institute in La Jolla, CA expected to serve as clinical model for Hope treatment offerings nationwide Kadima is a leading investigative site for CNS and psychedelic...
► Artikel lesen
05.05.NRx Pharmaceuticals beantragt Patent für konservierungsmittelfreies Ketamin3
05.05.NRx Pharmaceuticals seeks patent for preservative-free ketamine1
05.05.NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Patent Application for NRX-100, its Proprietary, Preservative Free Formulation of IV Ketamine56Patent expected to be Orange Book listable, if granted NRX-100, preservative free, IV ketamine, is designed to avoid potential toxicity concerns linked to benzethonium chloride, used...
► Artikel lesen
30.04.NRX Pharmaceuticals, Inc. - 10-K/A, Annual Report1
30.04.NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces FDA Award of Filing Fee Waiver for Upcoming NRX-100 (preservative free ketamine) New Drug Application to Treat Patients with Suicidal Depression46Waiver exempts NRx from paying a $4.3 million New Drug Application filing fee under the Prescription Drug User Fee Act (PDUFA) Company is on track for Q2 2025...
► Artikel lesen
17.04.NRX Pharmaceuticals, Inc. - 8-K, Current Report3
03.04.HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE83Investment to support initiation of HOPE's network of clinics to treat suicidal depression and PTSD with ketamine, TMS and other modalities MIAMI, April 3, 2025 /PRNewswire/ --...
► Artikel lesen
02.04.BTIG initiates NRx Pharmaceuticals with $18 price target3
31.03.NRx Pharma: HOPE Therapeutics Signs Deal To Buy Dura Medical3
31.03.NRx Pharmaceuticals' Hope Therapeutics to acquire Dura Medical, no terms2
21.03.NRX Pharmaceuticals, Inc. - 8-K, Current Report1
20.03.H.C. Wainwright maintains $19 target on NRx Pharmaceuticals stock6
19.03.Clario Buying Imaging Analysis Company NeuroRx2
17.03.Clario announces acquisition of imaging provider NeuroRx361Acquisition further builds on Clario's neuroscience expertise and capabilities PHILADELPHIA, March 17, 2025 /PRNewswire/ -- Clario, a leading provider of endpoint data solutions to...
► Artikel lesen
17.03.NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update129Initiated filing of a New Drug Application ("NDA") to the FDA for NRX-100 (IV Ketamine) for the treatment of Suicidal Depression; planned filing of an NDA for Accelerated Approval under...
► Artikel lesen
17.03.NRx Pharmaceuticals GAAP EPS of -$2.364
Seite:  Weiter >>
48 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1